New Alberta-developed cancer therapy showing 'remarkable results'
Adam Lachacz - 20 June 2022
A new trial gene therapy driven by Alberta research at Edmonton's Cross Cancer Institute is showing early successes researchers hope will offer more patients a stronger chance of regaining normalcy.
The Chimeric Antigen Receptor T-cell therapy (CAR-T) is used to treat youth and adults with certain types of lymphoma and leukemia for whom other forms of treatment, like chemotherapy, have stopped working.
Dr. Michael Chu, a University of Alberta assistant professor in oncology and lead clinician-scientist involved in the trial, said the new locally developed therapy is "game-changing."
"Being a one-time therapy gets people as close to back to normal as they can possibly get after a type of cancer treatment," Chu said. "It's going to really change how we administer medical therapy."